Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 571-577

  Al Tweigeri, Taher A ^a   Ajarim, Dahish S ^a   Alsayed, Adher A ^a   Rahal, Mohamed M ^a   Alshabanah, Mohamed O ^a   Tulbah, Asma M ^a   Al Malik, Osama A ^a   Fatani, Doha M ^a   El Husseiny, Gamal A ^a   Elkum, Naser B ^a   Ezzat, Adnan A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Anthracycline; Cisplatin docetaxel; Locally advanced breast cancer; Neoadjuvant chemotherapy; Pathologic complete response

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; ESTROGENS; FEMALE; GENES, ERBB-2; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; TAMOXIFEN; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956899986     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9251-7     Document Type: Article

References (35)

1. G Schwartsmann 2001 Breast cancer in South America: challenges to improve early detection and management of a public health problem J Clin Oncol 19 Suppl 18 118S 124S 11560986 1:STN:280:DC%2BD3MrhtlSqug%3D%3D
2. R Chopra 2001 The Indian scene J Clin Oncol 19 18 106S 111S 11560984 1:STN:280:DC%2BD3MrhtlSqtA%3D%3D
3. CA Adebamowo OO Adekunie 1999 Case controlled study of the epidemiological risk factors for breast cancer in Nigeria Br J Surg 86 665 668 10.1046/j.1365-2168.1999.01117.x 10361191 1:STN:280:DyaK1M3ptV2itQ%3D%3D (Pubitemid 29248362)
4. B Devi T Tang M Corbex 2007 Reduction by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical down staging in Sarawak, Malaysia Ann Oncol 18 1172 1176 10.1093/annonc/mdm105 17434897 1:STN:280:DC%2BD2svls1artQ%3D%3D (Pubitemid 47244362)
5. M Kaufmann G Von Minckwitz R Smith, et al. 2003 International expert panel on the use of primary systemic of operable breast cancer: review and recommendations J Clin Oncol 21 2600 2608 10.1200/JCO.2003.01.136 12829681 (Pubitemid 46606344)
6. I Sachelaria MI Grossbard M Chadha, et al. 2006 Primary systemic therapy of breast cancer Oncologist 11 564 589
7. HM Kuerer LA Newman TL Smith, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary and axillary lymph node response to doxorubicin based neoadjuvant chemotherapy J Clin Oncol 17 460 469 10080586 1:CAS:528:DyaK1MXht1Wmur4%3D
8. P Therasse L Mauriac M Welnicka-Jaskiewicz, et al. 2003 Final results of a randomised phase III trial comparing cyclophosphamide, epirubicin and 5 fluorouracil, with dose intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTIC-NCIC-SAKK multicenter study J Clin Oncol 21 843 850 10.1200/JCO.2003.05. 135 12610183 1:CAS:528:DC%2BD2cXpsVGqsr8%3D (Pubitemid 46606444)
9. G Von Minckwitz G Raab A Caputo, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685 10.1200/JCO.2005.05.078 1:CAS:528:DC%2BD2MXktleqtrw%3D (Pubitemid 46179457)
10. A Tafyli J Holter A Bova, et al. 2004 Activity of combination chemotherapy docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer Anticancer Res 26 4911 4916
11. GG Steger A Galid M Gnant, et al. 2007 Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14 J Clin Oncol 25 2012 2018 10.1200/JCO.2006.09.1777 17513805 1:CAS:528:DC%2BD2sXmvVWmsrc%3D (Pubitemid 46972785)
12. S Han SB Kim SS Kang, et al. 2006 A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer Breast Cancer Res Treat 98 57 61 10.1007/s10549-005-9131-6 16752226 1:CAS:528:DC%2BD28XmvVaqsbg%3D (Pubitemid 44050780)
13. TR Evans A Yellowlees E Foster, et al. 2005 Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo Celtic cooperative oncology group study J Clin Oncol 23 2988 2995 10.1200/JCO.2005.06.156 15860854 1:CAS:528:DC%2BD2MXkslGhu70%3D (Pubitemid 46224118)
14. G Von Minckwitz JU Blohmer G Raab, et al. 2005 In vivo chemosensitivity adopted preoperative chemotherapy in patients with early stage breast cancer: the GEPARTRIO pilot study Ann Oncol 16 56 63 10.1093/annonc/mdi001 (Pubitemid 40124479)
15. RM O'Regan JH Von Roenn RW Carleson, et al. 2005 Final results of phase II trial of preoperative TAC in stage III breast cancer Clin Breast Cancer 6 163 168 10.3816/CBC.2005.n.019 16001995
16. JP Crown 2001 The platinum agents: a role in breast cancer treatment Semin Oncol 28 28 37 10.1016/S0093-7754(01)90190-3 11301372 1:CAS:528: DC%2BD3MXjtFWqsrs%3D
17. W Zoli A Flamigi GL Frassinineti P Bajorko, et al. 1995 In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancer Breast Cancer Res Treat 34 63 69 10.1007/BF00666492 7749161 1:CAS:528:DyaK2MXkvVGnsbc%3D
18. C Belani T Lynch 2000 Docetaxel in combination with platinum in patients with non small cell lung cancer: trial data and implications for clinical management Semin Oncol 28 10 14
19. P Engblom V Rantaen J Kulmala, et al. 1999 Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines Br J Cancer 79 286 292 10.1038/sj.bjc.6690046 9888470 1:CAS:528: DyaK1MXmvFegtg%3D%3D
20. AA Ezzat MA Raja J Berry, et al. 1997 A phase II trial of circadian timed paclitaxel and cisplatin therapy in metastatic breast cancer Ann Oncol 8 663 667 10.1023/A:1008228121390 9296219 1:STN:280:DyaK2svkt1Sjsg%3D%3D (Pubitemid 27372164)
21. AA Ezzat EM Ibrahim DS Ajarim, et al. 2000 High complete pathologic response in locally advanced breast cancer using paclitaxel and cisplatin Breast Cancer Res Treat 62 237 244 10.1023/A:1006434406989 11072788 1:CAS:528:DC%2BD3cXnvV2quro%3D
22. AA Ezzat EM Ibrahim DS Ajarim, et al. 2004 Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients Br J Cancer 90 968 974 10.1038/sj.bjc.6601616 14997191 1:CAS:528:DC%2BD2cXhslWrs7Y%3D (Pubitemid 38495813)
23. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 10655437 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
24. JS Mieog JA van der Hage CJ van de Velde 2007 Neoadjuvant chemotherapy for operable breast cancer Br J Surg 94 1189 1200 10.1002/bjs.5894 17701939 1:STN:280:DC%2BD2srmslaktA%3D%3D (Pubitemid 47584766)
25. N Wolkman J Wang EP Mamounas, et al. 2001 Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel project B-18 J Natl Cancer Inst Monogr 30 96 102
26. P Rastogi SJ Anderson HD Bear, et al. 2008 Preoperative chemotherapy; updates of National Surgical Adjuvant Breast and Bowel project protocols B-18 and B-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
27. JA Van der Hage CJ van de Velde JP Julien, et al. 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of cancer trial 10902 J Clin Oncol 19 4224 4237 11709566
28. HD Bear S Anderson RE Smith, et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocols B-27 J Clin Oncol 24 2019 2027 10.1200/JCO.2005.04.1665 16606972 1:CAS:528:DC%2BD28Xlt1amur0%3D (Pubitemid 46622110)
29. JR Gralow HJ Burstein W Wood, et al. 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814 819 10.1200/JCO.2007.15.3510 18258991 (Pubitemid 351265335)
30. B Fisher A Brown E Mamounas, et al. 1997 Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer; findings from National Surgical Adjuvant Breast and Bowel project protocols B-18 J Clin Oncol 15 2483 2493 9215816 1:CAS:528:DyaK2sXkslymsr8%3D
31. IC Smith SD Heys AW Hutcheon, et al. 2002 Neoadjuvant chemotherapy in breast cancer significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466 10.1200/JCO.20.6.1456 11896092 1:CAS:528:DC%2BD38XivFeisbg%3D (Pubitemid 34260523)
32. YJ Lee P Doliny C Gomez-Fernandez, et al. 2004 Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancer Clin Breast Cancer 5 5 371 376 10.3816/CBC.2004.n.044 15585076 1:CAS:528: DC%2BD2MXmvVahsA%3D%3D
33. G Frasci G D'Aiuto R Thomas 2006 Weekly cisplatin, epirubicin and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study Br J Cancer 95 1005 1012 10.1038/sj.bjc.6603395 17047649 1:CAS:528:DC%2BD28XhtVyitbfP (Pubitemid 44606826)
34. IE Smith RP A'Hern GA Coombes, et al. 2004 A novel continuous infusional 5-fluorouracil based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial Ann Oncol 15 751 758 10.1093/annonc/mdh175 15111342 1:STN:280:DC%2BD2c3htFymsA%3D%3D (Pubitemid 38714736)
35. B Massidda F Atzori A Scanu, et al. 2007 Dose dense primary chemotherapy as part of multidisciplinary treatment for inoperable stage IIIB breast cancer, long term results of phase II trial Oncology 72 17 26 10.1159/000111084 17998786 (Pubitemid 350249124)